Principal Associate Scientist, RNAi Discovery jobs in United States
cer-icon
Apply on Employer Site
company-logo

Alnylam Pharmaceuticals · 2 months ago

Principal Associate Scientist, RNAi Discovery

Alnylam Pharmaceuticals is seeking a Principal Associate Scientist to join their High Throughput In Vitro team within the RNAi Discovery group. The role involves conducting in vitro research studies, managing high-throughput experiments, and contributing to the development of RNAi therapeutics.

BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
check
Comp. & Benefits
check
H1B Sponsor Likelynote

Responsibilities

Conduct a wide range of in vitro siRNA research studies to evaluate RNAi compounds using biochemical, molecular, and cell-based assays
Plan, coordinate, and execute day-to-day high-throughput in vitro experiments, including transfection, RNA extraction, qPCR, data upload, and statistical analysis
Design, perform, and interpret experiments independently and collaboratively, providing critical troubleshooting and technical insight
Maintain and culture various cell types (iPSCs, primary cells, immortalized cell lines) to support research objectives and facilitate high-throughput siRNA screening through qPCR and cell-based assays
Ensure accurate data recording, analysis, and timely reporting, preparing clear and detailed experimental summaries, documentation, and presentations
Identify and resolve technical challenges, contributing to the ongoing optimization and development of experimental protocols
Operate and maintain automated instrumentation and robotic systems to support high-throughput (384-well) screening workflows

Qualification

Vitro researchMammalian cell cultureMolecular biology techniquesNucleic acid therapeuticsLaboratory automation systemsExperimental designData interpretationScientific troubleshootingMicrosoft OfficeGraphPad PrismOrganizational skillsInterpersonal skillsTeam collaboration

Required

BS/MS in Biology, Molecular/Cell Biology, Biochemistry, or related field with 5–8 years of relevant experience, preferably in an industrial or biotech environment
Proficiency in mammalian cell culture, including maintenance and transfection of immortalized and primary cell lines
Skilled in molecular biology techniques for RNA, DNA, and protein quantification (qPCR, dPCR, Western blotting, ELISA, immunoprecipitation)
Strong knowledge of experimental design, data interpretation, and scientific troubleshooting
Highly detail-oriented, organized, and capable of managing multiple projects in a fast-paced, dynamic environment
Demonstrated ability to collaborate and communicate effectively with cross-functional teams and stakeholders
Proficiency with Microsoft Office (Excel, Outlook, PowerPoint, Word) and GraphPad Prism

Preferred

Prior experience or strong understanding of nucleic acid–based therapeutics (siRNA, ASO, CRISPR) highly desired
Hands-on experience with laboratory automation systems, including liquid-handling platforms such as PerkinElmer JANUS, Beckman i7, or similar

Benefits

Comprehensive benefits including medical, dental, and vision coverage
Life and disability insurance
A lifestyle reimbursement program
Flexible spending and health savings accounts
A 401(k) with a generous company match
Paid time off
Wellness days
Holidays
Two company-wide recharge breaks
Generous family resources and leave

Company

Alnylam Pharmaceuticals

company-logo
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.

H1B Sponsorship

Alnylam Pharmaceuticals has a track record of offering H1B sponsorships. Please note that this does not guarantee sponsorship for this specific role. Below presents additional info for your reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2022 (18)
2021 (19)
2020 (7)

Funding

Current Stage
Public Company
Total Funding
$4.55B
Key Investors
Blackstone Life SciencesBlackstone CreditRegeneron
2025-09-09Post Ipo Debt· $661.25M
2022-09-12Post Ipo Debt· $900M
2022-03-04IPO

Leadership Team

leader-logo
Yvonne Greenstreet
Chief Executive Officer
linkedin
leader-logo
Jeff Poulton
Chief Financial Officer
linkedin
Company data provided by crunchbase